Medifun Lancing Device, Model No. LD-E1

K231797 · Medifun Corporation · QRL · Nov 22, 2023 · General, Plastic Surgery

Device Facts

• Record ID: K231797
• Device Name: Medifun Lancing Device, Model No. LD-E1
• Applicant: Medifun Corporation
• Product Code: QRL · General, Plastic Surgery
• Decision Date: Nov 22, 2023
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4850
• Device Class: Class 2

Intended Use

Medifun Lancing Device, Model No. LD-E1 is a reusable lancing device for the single user. It should be used with the proper sterile lancet for the capillary blood sampling. It could automatically inject the lancet into and retract it from the fingertip to obtain a capillary blood sample for glucose monitoring or other test that require one or two drops of blood. A depth adjustable cap allows the best depth of skin penetration for each individual user. Alternative site testing (palm or forearm) can be performed by installing the clear cap on the lancing device.

Device Story

Mechanical, spring-driven lancing device; used by single patient for capillary blood sampling. User inserts sterile lancet; device automatically injects and retracts lancet into skin. Features 6-level depth-adjustable cap for penetration control; clear cap included for alternative site testing. Used in home or clinical settings; operated by patient. Output is capillary blood sample for diagnostic testing. Benefits patient by providing controlled, consistent skin penetration for blood collection.

Clinical Evidence

Bench testing only. No clinical data. Testing included ISO 10993-5 (cytotoxicity), ISO 10993-23 (skin irritation), ISO 10993-10 (skin sensitization), cleaning validation, and functional/mechanical design verification.

Technological Characteristics

Mechanical spring-driven lancing device. Materials: ABS plastic, Polyoxymethylene, SUS304 stainless-steel springs. 6 depth settings (0.5mm-1.7mm). Non-sterile. Single-patient use. No software or electronics.

Indications for Use

Indicated for single-user capillary blood sampling from fingertip or alternative sites (palm, forearm) for glucose monitoring or other tests requiring 1-2 drops of blood.

Regulatory Classification

Identification

The regulation covers four types of blood lancets: (a) Single use only blood lancet with an integral sharps injury prevention feature; (b) Single use only blood lancet without an integral sharps injury prevention feature; (c) Multiple use blood lancet for single patient use only; and (d) Multiple use blood lancet for multiple patient use. All are defined as disposable or reusable devices comprised of a blade attached to a base used to puncture the skin to obtain a drop of blood for diagnostic purposes.

Special Controls

*Classification.* Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that the structure and material composition are consistent with the intended use and must include a sharps injury prevention feature. (ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use and that the integral sharps injury prevention feature will irreversibly disable the device after one use. (iii) The device must be demonstrated to be biocompatible. (iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin ( *e.g.,* blade).(v) Labeling must include: (A) Detailed descriptions, with illustrations, of the proper use of the device and its sharps injury prevention feature. (B) Handwashing instructions for the user before and after use of the device. (C) Instructions on preparation ( *e.g.,* cleaning, disinfection) of the skin to be pierced.(D) Instructions for the safe disposal of the device. (E) Labeling must be appropriate for the intended use environment. ( *1* ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.( *2* ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vi) Labeling must also include the following statements, prominently placed: (A) “For use only on a single patient. Discard the entire device after use.” (B) “Warning: Not intended for more than one use. Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested.” (b) *Single use only blood lancet without an integral sharps injury prevention feature* —(1)*Identification.* A disposable blood lancet intended for a single use that is comprised of a single use blade attached to a solid, non-reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2) *Classification.* Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that the structure and material composition are consistent with the intended use and address the risk of sharp object injuries and bloodborne pathogen transmissions. (ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use. (iii) The device must be demonstrated to be biocompatible. (iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin ( *e.g.,* blade).(v) Labeling must include: (A) Detailed descriptions, with illustrations, of the proper use of the device. (B) Handwashing instructions for the user before and after use of the device. (C) Instructions on preparation ( *e.g.,* cleaning, disinfection) of the skin to be pierced.(D) Instructions for the safe disposal of the device. (E) Labeling must be appropriate for the intended use environment. ( *1* ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.( *2* ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vi) Labeling must also include the following statements, prominently placed: (A) “For use only on a single patient. Discard the entire device after use.” (B) “Warning: Not intended for more than one use. Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested.” (c) *Multiple use blood lancet for single patient use only* —(1)*Identification.* A multiple use capable blood lancet intended for use on a single patient that is comprised of a single use blade attached to a solid, reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2) *Classification.* Class II (special controls). The special controls are:(i) The design characteristics of the device must ensure that: (A) The lancet blade can be changed with every use, either manually or by triggering a blade storage unit to discard the used blade and reload an unused blade into the reusable base; and (B) The structure and material composition are consistent with the intended use and address the risk of sharp object injuries and bloodborne pathogen transmissions and allow for validated cleaning and disinfection. (ii) Mechanical performance testing must demonstrate that the device will withstand forces encountered during use. (iii) The device must be demonstrated to be biocompatible. (iv) Sterility testing must demonstrate the sterility of any device component that breaches the skin ( *e.g.,* blade).(v) Validation testing must demonstrate that the cleaning and disinfection instructions are adequate to ensure that the reusable lancet base can be cleaned and low level disinfected. (vi) Labeling must include: (A) Detailed descriptions, with illustrations, of the proper use of the device. (B) The Environmental Protection Agency (EPA) registered disinfectant's contact time for disinfectant use. (C) Handwashing instructions for the user before and after use of the device. (D) Instructions on preparation ( *e.g.,* cleaning, disinfection) of the skin to be pierced.(E) Instructions on the cleaning and disinfection of the device. (F) Instructions for the safe disposal of the device. (G) Instructions for use must address the safe storage of the reusable blood lancet base between uses to minimize contamination or damage and the safe storage and disposal of the refill lancet blades. (H) Labeling must be appropriate for the intended use environment. ( *1* ) For those devices intended for health care settings, labeling must address the health care facility use of these devices, including how these lancets are to be used with personal protective equipment, such as gloves.( *2* ) For those devices intended for use in the home, labeling must be written so that it is understandable to lay users.(vii) Labeling must also include the following statements, prominently placed: (A) “For use only on a single patient. Disinfect reusable components according to manufacturer's instructions between each use.” (B) “Used lancet blades must be safely discarded after a single use.” (C) “Warning: Do not use on more than one patient. Improper use of blood lancets can increase the risk of inadvertent transmission of bloodborne pathogens, particularly in settings where multiple patients are tested. The cleaning and disinfection instructions for this device are intended only to reduce the risk of local use site infection; they cannot render this device safe for use for more than one patient.” (d) *Multiple use blood lancet for multiple patient use* —(1)*Identification.* A multiple use capable blood lancet intended for use on multiple patients that is comprised of a single use blade attached to a solid, reusable base that is used to puncture the skin to obtain a drop of blood for diagnostic purposes.(2) *Classification.* Class III (premarket approval).(3) *Date PMA or notice of completion of a PDP is required:* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before May 22, 2024, for any multiple use blood lancet for multiple patient use described in paragraph (d)(1) of this section that was in commercial distribution before May 28, 1976, or that has, on or before May 22, 2024, been found to be substantially equivalent to a multiple use blood lancet for multiple patient use described in paragraph (d)(1) of this section that was in commercial distribution before May 28, 1976. Any other multiple use blood lancet for multiple patient use shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• RIGHTEST Lancing Device GD500 (K221062)
• GE Lancing Device (K221062)
• iGlucose Lancing Device (K221062)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. Food & Drug Administration".

November 22, 2023

Medifun Corporation Tyra Chiu Regulatory Consultant VOLER Biotech Consulting Co., Ltd. IF. No 3-1. Ln. 58. Hejiang St., Zhongshan Dist, Taipei, 104 Taiwan

Re: K231797

Trade/Device Name: Medifun Lancing Device, Model No. LD-E1 Regulation Number: 21 CFR 878.4850 Regulation Name: Blood Lancets Regulatory Class: Class II Product Code: QRL Dated: August 25, 2023 Received: September 5, 2023

Dear Tyra Chiu:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Mark Mark
Trumbore -S -S -S -S -S Mark Trumbore, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K231797

Device Name Medifun Lancing Device, Model No. LD-E1

#### Indications for Use (Describe)

Medifun Lancing Device, Model No. LD-E1 is a reusable lancing device for the single user. Itshould be used with the proper sterile lancet for the capillary blood sampling. It could automatically inject the lancet into and retract it from the fingertip to obtain a capillary blood sample for glucose monitoring or other test that require one or two drops of blood. A depth adjustable cap allows the best depth of skin penetration for each individual user. Alternative site testing (palm or forearm) can be performed by installing the clear cap on the lancing device.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|------------------------------------------------------------|
| <span></span> | |
| | <span></span> Prescription Use (Part 21 CFR 801 Subpart D) |
| | <span></span> Over-The-Counter Use (21 CFR 801 Subpart C) |

ounter Use (21 CFR 801 Suppart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary

May 09, 2023 Date

| Manufacturer/ | Medifun Corporation |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) Owner | 4F-1, 4F-9, 4F-10, No.99, Jingke S. Rd., Nantun Dist., Taichung City<br>408, Taiwan (R.O.C.) |
| Contact Person | Aaron Chen |
| Device Trade Name | Medifun Lancing Device, Model No. LD-E1 |
| Common Name | Multiple Use Blood Lancet For Single<br>Patient Use Only |
| Classification Name | Multiple Use Blood Lancet For Single<br>Patient Use Only |
| Device Class | II |
| Classification Panel | General & Plastic Surgery |
| Regelation Number | 21 CFR 878.4850 |
| Product Code | QRL |
| Device Description<br>and Technology<br>Characteristics | Medifun Lancing Device, Model No. LD-E1 is a mechanical blood lancet<br>holder. It is used with a single use sterile lancet to puncture the skin for<br>collecting capillary whole blood sampled from the fingertip or alternate<br>sites. Medifun Lancing Device LD-E1 can be adjusted for 6 levels of<br>depth. This device is for single user only. |
| Indications for Use | Medifun Lancing Device, Model No. LD-E1 is a reusable lancing device<br>for the single user. Itshould be used with the proper sterile lancet for the<br>capillary blood sampling. It could automatically inject the lancet into and<br>retract it from the fingertip to obtain a capillary blood sample for glucose<br>monitoring or other test that require one or two drops of blood. A depth<br>adjustable cap allows the best depth of skin penetration for each individual<br>user. Alternative site testing (palm or forearm) can be performed by<br>installing the clear cap on the lancing device. |
| Predicate Device(s) | RIGHTEST Lancing Device GD500, GE Lancing Device,<br>iGlucose Lancing Device, submitted by Bionime<br>Corporation<br>K221062 |

Discussion on Non-clinical bench testing was performed to ensure predetermined Performance Data criteria were met and the special controls were satisfied. This includes Non-Clinical Tests mechanical design verification and validation testing in order to ensure the risks were appropriately managed in addition to, verifying that the

{4}------------------------------------------------

device continued to meet the specified requirements. The following nonclinical tests were conducted to evaluate the safety and performance of the subject device and provide evidence to support the verification and validation:

- ISO 10993-5 In vitro Cytotoxicity -
- ISO 10993-23 Skin Irritation -
- ISO 10993-10 Skin Sensitization -
- cleaning validation -
- Risk management according to ISO 14971:2019. -
- Specification and functional tests -

The subject device has same indications for use, technology, and Substantial Equivalence operation principle as well as similar technical characteristics with the predicate device. Verification activities were performed on subject device and all tests were verified to meet the required acceptance criteria. The verification tests demonstrate that the differences in the device do not affect the intended use of the device or raise any unsolved issues. There are no significant differences between subject device and the predicate device(s). We conclude that subject device is substantially equivalent to predicate devices.

- Based on the information provided in this premarket notification, we Conclusion believe the proposed Medifun Lancing Device, Model No. LD-E1 and its predicate device are substantially equivalent in their intended use, both devices share similar design and technology characteristics.

{5}------------------------------------------------

## Summary of Comparison and Technological Characteristics

| | Proposed Device | Predicate Device | Substantial Equivalence Comparison |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Device Name | Medifun Lancing Device , Model No. LD-E1 | RIGHTEST Lancing Device GD500,<br>GE Lancing Device and iGlucose<br>Lancing Device | - |
| 510(k) # | - | K221062 | - |
| Product code | QRL | QRL | Identical |
| Classification | Class II | Class II | Identical |
| Intended Use | Medifun Lancing Device, Model No. LD-E1 is a reusable lancing device for the single user. It should be used with the proper sterile lancet for the capillary blood sampling. It could automatically inject the lancet into and retract it from the fingertip to obtain a capillary blood sample for glucose monitoring or other test that require one or two drops of blood. A depth adjustable cap allows the best depth of | RIGHTEST Lancing Device GD500 is a reusable lancing device for the single user. It should be used with the proper sterile lancet for the capillary blood sampling. It could automatically inject the lancet into and retract it from the fingertip to obtain a capillary blood sample for glucose monitoring or other test that require one or two drops of blood. A depth adjustable cap allows the | Identical |

{6}------------------------------------------------

| skin penetration for each individual user.<br>Alternative site testing (palm or forearm)<br>can be performed by installing the clear<br>cap on the lancing device. | best depth of skin penetration for each<br>individual user. Alternative site testing<br>(palm or forearm) can be performed by<br>installing the clear cap on the lancing<br>device.<br>GE Lancing Device is a reusable lancing<br>device for the single user. It should be<br>used with the proper sterile lancet for the<br>capillary blood sampling. It could<br>automatically inject the lancet into and<br>retract it from the fingertip to obtain a<br>capillary blood sample for glucose<br>monitoring or other test that require one<br>or two drops of blood. A depth adjustable<br>cap allows the best depth of skin<br>penetration for each individual user.<br>Alternative site testing<br>(palm or forearm) can be performed by<br>installing the clear cap on the lancing |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

{7}------------------------------------------------

| | | device. | |
|---------------------------|--------------------------------------------------------------|----------------------------------------------|-----------|
| | | iGlucose Lancing Device is a reusable | |
| | | lancing device for the single user. It | |
| | | should be used with the proper sterile | |
| | | lancet for the capillary blood sampling. It | |
| | | could automatically inject the lancet into | |
| | | and retract it from the fingertip to obtain | |
| | | a capillary blood sample for glucose | |
| | | monitoring or other test that require one | |
| | | or two drops of blood. A depth adjustable | |
| | | cap allows the best depth of skin | |
| | | penetration for each individual user. | |
| OTC/ Prescription Use | OTC | OTC | Identical |
| Operation Principle | Mechanical puncture device to obtain micro | Mechanical puncture device to obtain | Identical |
| | blood samples | micro blood samples | |
| Materials of construction | ABS plastic, Polyoxymethylene, SUS304 | - | Different |
| | stainless-steel springs | | |
| Depth Adjustment | 6 different depths, 0.5mm-1.7 mm | 7 different depths, 0.5 mm- 1.7 mm. | Similar |
| Loading and Firing | Mechanical, Spring-driven | Mechanical, Spring-driven | Identical |
| Sharps Injury Prevention | Lancet retract after use | Lancet retract after use | Identical |
| Device Sterility | Non-sterile | Non-sterile | Identical |
| Number of Use | multiple use for single patient only | multiple use for single patient only | Identical |
| Biocompatibility | ISO 10993-1,<br>ISO 10993-5,<br>ISO 10993-10<br>ISO 10993-23 | ISO 10993-1,<br>ISO 10993-5,<br>ISO 10993-10 | Identical |

{8}------------------------------------------------